Archives

Selexis Promotes Dr. Yemi Onakunle to Chief Business Officer

Teneobio and Selexis Expand Relationship with Three Commercial License Agreements for Multi-specific Antibody Candidates in Oncology

Generium Launches First Biosimilar of Dornase Alfa; Becomes Sixth Approved Product Using Selexis SUREtechnology Platform

ZyVersa Therapeutics to Advance Development of Its Lead Inflammasome Inhibitor with Selexis and KBI Biopharma’s Integrated Development Platform

Avacta and Selexis Partner to Develop Cell Line for Clinical Manufacturing